Market Overview

One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings

Share:
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
Related BMY
A Peek Into The Markets: US Stock Futures Gain Ahead Of Citigroup, Wells Fargo Earnings
Bristol-Myers, Disney, ETP, Paypal: 'Fast Money' Picks For October 9
Neon Therapeutics Is An Emerging Player In Personalized Immunotherapy With Catalysts Ahead (Seeking Alpha)
Related MRK
4 Major Market Opportunities For The Cannabis Industry
The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
Neon Therapeutics Is An Emerging Player In Personalized Immunotherapy With Catalysts Ahead (Seeking Alpha)

Merck & Co., Inc. (NYSE: MRK)’s Keytruda returned better-than-expected results in the Keynote-189 lung study — a feat seen to lend a competitive edge over Bristol-Myers Squibb Co (NYSE: BMY).

The Rating

Morgan Stanley analyst David Risinger upgraded Merck from Equal-weight to Overweight and increased the price target from $63 to $68.

At the same time, he downgraded Bristol-Myers from Overweight to Equal-weight and slashed the price target from $78 to $58.

The Thesis

Keytruda beat out Bristol-Myers’ Opdivo-Yervoy combination in both the progression-free survival hazard ratio and overall survival in a chemo combination. By comparison, the Bristol-Myers data appears “disappointing," Risinger said in a Tuesday note.

“Although the BMY survival figure should improve with longer follow up, we think it is unlikely to match Merck’s impressive results,” Risinger said, noting the latter will maintain its lead in the largest cancer market.

Morgan Stanley increased 2023 Keytruda revenue forecasts by 13 percent to represent a doubling of sales over five years. Estimates for 2019 earned a 10-percent boost. The two correlate with respective 8-percent and 5-percent increases in EPS forecasts.

Morgan Stanley lowered its estimates for 2019 Opdivo sales by 17 percent, leading to a projected 5-percent drop in total revenue and 8-percent fall in EPS. Looking five years out, Risinger lowered Bristol-Myers’ top-line expectations by 13 percent and bottom line by 21 percent on “lower growth projections and diminished prospects for strategic optionality.”

It is worth noting that Opdivo is expected to outperform Keytruda in non-1L lung indications, yielding an opportunity in second-line non-squamous NSCLC. Upcoming 1L squamous results from Merck and Roche will determine Opdivo’s potential in second-line non-squamous NSCLC, Risinger said. 

Merck has additional opportunity to advance Keytruda in other tumors and earlier-stage therapies, and it will also release updates on novel vaccines and HIV products throughout the next year, according to Morgan Stanley. 

Price Action

At the time of publication, Merck was trading up 1.7 percent and Bristol-Myers down 2.3 percent.

Related Links:

What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy

Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2018BarclaysMaintainsEqual-WeightEqual-Weight
Oct 2018JP MorganMaintainsOverweightOverweight
Aug 2018Atlantic EquitiesUpgradesUnderweightNeutral

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Analyst Color Upgrades Downgrades Health Care Price Target Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

ADP Vs. Paychex: Bank Of America Picks A Winner

Benzinga's Top Analyst Calls From April 17, 2018